Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PSA/Prostate screening

Share :

2009 ASCO Annual Meeting

29 May - 2 Jun 2009
Published: 25 Jun 2009
Views: 13652
Rating:
Save
Dr. Otis W. Brawley - Chief Medical Officer, ASCO
Prostate cancer screening studies and ASCO 2009

Related Videos

Looking into the future diagnosis and treatment options for prostate cancer in...
Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA
Looking into the future diagnosis and treatment options for prostate cancer in Africa ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )
25 May 2023
Management of prostate cancer in Africa: Looking to the future
Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA
Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )
25 May 2023
Introduction to iCCaRE Consortium for Black Men
Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina
Introduction to iCCaRE Consortium for Black Men ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )
9 May 2023
A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC...
Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA
A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients ( Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA )
20 Apr 2023
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Dr Roger Li - Moffitt Cancer Center, Tampa, USA
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )
22 Mar 2023
ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance
Prof Heather Payne and Dr Jochen Walz
ASCO GU 2023: Prostate QoL data and apalutamide plus active surveillance ( Prof Heather Payne and Dr Jochen Walz )
21 Mar 2023
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...
Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Mar 2023
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...
Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...
Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation